Could we apply the criteria of DAWN and DEFUSE-3 trials for slow progressors, beyond 24 h?

Acta Neurol Belg. 2020 Aug;120(4):977-980. doi: 10.1007/s13760-020-01277-7. Epub 2020 Jan 18.

Authors

François Delvoye¹, Jean-Philippe Desilles^{2

3}, Mikael Mazighi^{2

3}

Affiliations

¹ Interventional Neuroradiology Department, Fondation Ophtalmologique Adolphe de Rothschild, Rue Manin 25, 75019, Paris, France. fdelvoye@for.paris.
² Interventional Neuroradiology Department, Fondation Ophtalmologique Adolphe de Rothschild, Rue Manin 25, 75019, Paris, France.
³ Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, Paris, France.

PMID: 31955392
DOI: 10.1007/s13760-020-01277-7

No abstract available

Keywords: Acute stroke; Collaterals; Endovascular treatment; Slow progressors.

Publication types

Case Reports
Letter

MeSH terms

Aged
Fibrinolytic Agents / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Ischemic Stroke / therapy*
Male
Randomized Controlled Trials as Topic
Thrombectomy / methods
Time Factors

Substances

Fibrinolytic Agents
Heparin, Low-Molecular-Weight